Viral Hepatitis B and C

被引：0
作者：
Reiser, Markus [1 ]
机构：
[1] Behandlungszentrum Paracelsus Klin Marl, Klinikum Vest GmbH, Innere Med Klin, D-45770 Marl, Germany
来源：
MEDIZINISCHE KLINIK | 2009年 / 104卷 / 05期
关键词：
Hepatitis B; Hepatitis C; Antiviral therapy; Interferon alfa; Peginterferon; Albinterferon; Protease inhibitors; RNA polymerase inhibitors; Telaprevir; Boceprevir; Nucleotide analogs; Nucleoside analogs; ANTIVIRAL ACTIVITY; VIROLOGICAL RESPONSE; THERAPY; PEGINTERFERON-ALPHA-2A; COMBINATION; LAMIVUDINE; RIBAVIRIN; R1626; DURABILITY; TELAPREVIR;
D O I：
10.1007/s00063-009-1074-y
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chronic hepatitis B (HBV) and C virus (HCV) infection can lead to liver cirrhosis, hepatocellular carcinoma and death. Treatment of these worldwide prevalent infectious diseases is subject to intensive research efforts with development of new antiviral substances and optimization of treatment strategies using molecular markers. The goal of HBV and HCV treatment is control and elimination of viral replication, respectively, thereby preventing hepatitis-associated complications. While interferon alfa is used less frequently to treat hepatitis B today, it is still (in the pegylated or albumin-fused form) an essential component of hepatitis C therapy. The growing number of targeted therapies such as new nucleos(t)ide analogs, HCV protease and RNA polymerase inhibitors and other new compounds has added complexity to the treatment of viral hepatitis. This update summarizes the current standard of care as well as new developments in chronic hepatitis B and C therapy.
引用
收藏
页码：356 / 362
页数：7
相关论文
共 35 条
[1]   Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy [J].
Berg, T ;
Sarrazin, C ;
Herrmann, E ;
Hinrichsen, H ;
Gerlach, T ;
Zachoval, R ;
Wiedenmann, B ;
Hopf, U ;
Zeuzem, S .
HEPATOLOGY, 2003, 37 (03) :600-609
[2]   Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues [J].
Buster, Erik H. C. J. ;
Schalm, Solko W. ;
Janssen, Harry L. A. .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2008, 22 (06) :1093-1108
[3]   Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV-)infection: upgrade of the guideline, AWMF-Register 021/011 [J].
Cornberg, M. ;
Protzer, U. ;
Dollinger, M. M. ;
Petersen, J. ;
Wedemeyer, H. ;
Berg, T. ;
Jilg, W. ;
Erhardt, A. ;
Wirth, S. ;
Schirmacher, P. ;
Fleig, W. E. ;
Manns, M. P. .
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2007, 45 (06) :525-574
[4]   Durability of serologic response after lamivudine treatment of chronic hepatitis B [J].
Dienstag, JL ;
Cianciara, J ;
Karayalcin, S ;
Kowdley, KV ;
Willems, B ;
Plisek, S ;
Woessner, M ;
Gardner, S ;
Schiff, E .
HEPATOLOGY, 2003, 37 (04) :748-755
[5]   Drug therapy - Hepatitis B virus infection [J].
Dienstag, Jules L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (14) :1486-1500
[6]  
DUSHEIKO GM, 2008, 43 ANN M EUR ASS STU
[7]   Treatment with Peg-interferon α-2b for HBeAg-positive chronic hepatitis B:: HBsAg loss is associated with HBV genotype [J].
Flink, HJ ;
van Zonneveld, M ;
Hansen, BE ;
de Man, RA ;
Schalm, SW ;
Janssen, HLA .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (02) :297-303
[8]   Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C [J].
Forestier, Nicole ;
Reesink, Hendrik W. ;
Weegink, Christine J. ;
McNair, Lindsay ;
Kieffer, Tara L. ;
Chu, Hui-May ;
Purdy, Susan ;
Jansen, Peter L. M. ;
Zeuzem, Stefan .
HEPATOLOGY, 2007, 46 (03) :640-648
[9]   Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy [J].
Formann, E ;
Steindl-Munda, P ;
Hofer, H ;
Jessner, W ;
Bergholz, U ;
Gurguta, C ;
Ferenci, P .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (04) :507-511
[10]   Treatment of HBeAg-negative chronic hepatitis B [J].
Hadziyannis, SJ ;
Papatheodoridis, GV ;
Vassilopoulos, D .
SEMINARS IN LIVER DISEASE, 2003, 23 (01) :81-88
1234